InMode 配当と自社株買い
配当金 基準チェック /06
InMode配当金を支払った記録がありません。
主要情報
n/a
配当利回り
6.8%
バイバック利回り
| 総株主利回り | 6.8% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブの更新 • May 03
INMD: Buyback Plan And 2026 Guidance Will Support A Measured Outlook
Analysts kept their $15.00 price target for InMode unchanged, noting only minor shifts in inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the basis for maintaining their view. What's in the News InMode issued revenue guidance for the first quarter of 2026, with expected revenue in a range of $81.5 million to $81.7 million, and reiterated its full year 2026 revenue outlook of $365 million to $375 million (Corporate Guidance).ナラティブの更新 • Apr 19
INMD: Takeover Talks And Buyback Plan Will Shape A Measured Outlook
InMode's updated analyst price target remains at $15.00, with analysts pointing to small shifts in the discount rate, revenue growth assumptions, profit margin, and future P/E as the key drivers behind the reaffirmed valuation view. What's in the News Media report that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, pointing to ongoing interest from financial buyers (Calcalist).ナラティブの更新 • Apr 03
INMD: Potential Takeover Talks And Buyback Plan Will Shape A Balanced Outlook
Analysts have maintained their $15.00 price target for InMode, citing small adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E that did not materially affect their overall valuation view. What's in the News Media reports indicate InMode is in talks to be sold for about US$1.1b to a foreign investment fund, highlighting ongoing interest from financial buyers (Calcalist).ナラティブの更新 • Mar 20
INMD: Potential Sale Talks And Buyback Plan Will Shape A Measured Outlook
Analysts have kept their $15.00 price target on InMode unchanged, citing only very small tweaks to model inputs around discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the stock. What's in the News Media report that InMode is in talks to be sold for about US$1.1 billion to a foreign investment fund, according to Calcalist (Calcalist).ナラティブの更新 • Mar 05
INMD: Potential Sale And Earnings Guidance Will Shape A Measured Forward View
Analysts have kept their $15.00 price target on InMode unchanged, citing only marginal tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that did not materially alter their overall view of the stock. What's in the News Calcalist reports that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, indicating ongoing interest in potential ownership changes (Calcalist).ナラティブの更新 • Feb 19
INMD: Potential Sale Talks And Earnings Guidance Will Shape A Balanced Outlook
Analysts kept their $15.00 price target for InMode steady, citing only slight adjustments in assumptions such as discount rate, revenue growth, profit margin, and future P/E as reasons for maintaining their view rather than making a material change. What's in the News Media report that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, according to Calcalist (Periodical).Seeking Alpha • Feb 18
InMode: Some Green Shoots Appearing, But The Market Hasn't Noticed
Summary InMode Ltd. remains a Strong Buy at current levels, supported by a robust balance sheet, proprietary technology, and international growth. Green shoots include a 2.7% rise in consumables/servicing revenue and 14.5% international sales growth, offsetting possible U.S. market saturation. Management guides for flat 2026 revenue, with new product launches and expanding international footprint positioning INMD for future upside. Despite management frustrations and takeover rumors, INMD's very low valuation and strong cash position offer compelling risk-reward for recovery-focused investors. Read the full article on Seeking Alphaナラティブの更新 • Feb 04
INMD: Potential Sale Talks And Guidance Will Sustain A Cautious Fair Value View
Analysts have kept their price target for InMode steady at US$15.00, with only minor model tweaks to the discount rate, revenue growth, profit margin and assumed future P/E feeding into this unchanged view. What's in the News Media report that InMode is in talks to be sold to a foreign investment fund in a transaction valued at about US$1.1 billion, indicating active interest in the company from financial buyers (Periodical, Calcalist).ナラティブの更新 • Jan 21
INMD: Refreshed Guidance And Margin Outlook Will Support A Cautious Fair Value Stance
Analysts now see InMode's fair value holding at $15.00. The refreshed price target framework mainly reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in the headline valuation level.分析記事 • Jan 07
InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...ナラティブの更新 • Jan 06
INMD: Reaffirmed 2025 Revenue Guidance Will Underpin A Cautious Fairly Valued Outlook
Analysts have nudged their price target on InMode slightly higher to US$15.00 from US$15.00. This reflects small tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E that, in their view, modestly refine rather than overhaul the prior outlook.ナラティブの更新 • Dec 13
INMD: Revenue Outlook And Legal Overhang Will Shape A Cautious 2025 Outlook
Analysts have raised their price target on InMode by 1.00 dollar, reflecting improved expectations for a return to modest top line growth and slightly higher long term profitability multiples. What's in the News InMode reaffirmed its full year 2025 revenue outlook, maintaining guidance at $365 million to $375 million.分析記事 • Nov 12
There Might Be More To InMode's (NASDAQ:INMD) Story Than Just Weak Earnings
Shareholders didn't appear too concerned by InMode Ltd.'s ( NASDAQ:INMD ) weak earnings. We did some digging, and we...分析記事 • Jul 31
Should You Think About Buying InMode Ltd. (NASDAQ:INMD) Now?
InMode Ltd. ( NASDAQ:INMD ), might not be a large cap stock, but it saw significant share price movement during recent...分析記事 • Jun 30
An Intrinsic Calculation For InMode Ltd. (NASDAQ:INMD) Suggests It's 36% Undervalued
Key Insights InMode's estimated fair value is US$22.05 based on 2 Stage Free Cash Flow to Equity InMode's US$14.19...分析記事 • May 21
InMode (NASDAQ:INMD) Might Be Having Difficulty Using Its Capital Effectively
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Seeking Alpha • Apr 29
InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)
Summary InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects. Given the revenue declines and strategic uncertainties, I downgrade InMode to Hold, recommending caution until significant positive developments occur. Read the full article on Seeking Alpha分析記事 • Apr 26
Is Now The Time To Look At Buying InMode Ltd. (NASDAQ:INMD)?
While InMode Ltd. ( NASDAQ:INMD ) might not have the largest market cap around , it saw a decent share price growth of...分析記事 • Apr 11
Investors Don't See Light At End Of InMode Ltd.'s (NASDAQ:INMD) Tunnel And Push Stock Down 25%
InMode Ltd. ( NASDAQ:INMD ) shares have had a horrible month, losing 25% after a relatively good period beforehand...Seeking Alpha • Feb 10
InMode: Plastic Surgery Boom, Cash Flow, And Cheap
Summary InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability. Despite lower 2024 revenue, new product launches and international efforts indicate promising growth potential from 2025 to 2031. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
InMode: A Clear Bargain With Unique Risks
Summary InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based technologies. InMode's robust balance sheet and high profit margins support a substantial margin of safety at current prices, despite risks. Read the full article on Seeking Alpha分析記事 • Jan 08
An Intrinsic Calculation For InMode Ltd. (NASDAQ:INMD) Suggests It's 50% Undervalued
Key Insights InMode's estimated fair value is US$34.79 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Dec 12
InMode: Product Origination And Undervaluation Make The Stock A Buy
Summary InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative technologies in plastic surgery, dermatology, gynecology, and ophthalmology, along with ongoing stock repurchases, make InMode a compelling buy. Strong financials show consistent income growth and significant cash flow, with minimal liabilities, indicating a robust financial position and undervaluation. Expansion into new markets, enhanced sales force, and continuous R&D in new treatment areas promise sustained revenue and free cash flow growth. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
InMode: $25/Share Is Closer Than You Think
Summary Elevated interest rates continue to hurt InMode’s revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy back shares at a low price, which will boost per-share results. InMode's manufacturing is done in Israel, presenting a risk, but the company has been managing this well despite the war. The stock is undervalued, with only modest FCF/share growth needed to achieve a $25 fair value. And this FCF/share growth can be supported by more buybacks. Organizational shifts don't have me worried at the moment, but they are worth monitoring because they present uncertainty. Read the full article on Seeking Alpha分析記事 • Nov 01
InMode Ltd. Just Recorded A 17% EPS Beat: Here's What Analysts Are Forecasting Next
InMode Ltd. ( NASDAQ:INMD ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • Sep 24
InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
新しいナラティブ • Sep 24
Innovations And Global Expansion Poised To Propel Medical Tech Leader To New Heights
Introduction of IgniteRF and Optimus Max platforms, alongside FDA clearance for Morpheus8, drives revenue growth through market penetration and expanding patient base.Seeking Alpha • Sep 19
InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)
Summary InMode’s Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slower platform rollouts and production delays. Lower interest rates from Federal Reserve cuts could boost demand for InMode's minimally invasive treatments, benefiting from reduced financing costs. New platforms IgniteRF and OptimasMAX are expected to drive future growth, appealing to clinics seeking cost-effective solutions. Despite short-term revenue declines, InMode’s attractive valuation and new growth catalysts position it as a "buy" opportunity. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
Summary InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook. Despite geopolitical risks, InMode's strong cash position, profitability, and the growing aesthetics market make it a long-term investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
InMode: Still Undervalued, But Short-Term Risks Warrant Caution (Rating Downgrade)
Summary Despite INMD being down -22% since I recommended to Buy the stock in March, InMode Ltd. remains a highly profitable & innovative leader in the aesthetic industry. Stronger than expected macroeconomic pressures and the slow but continuing escalation of the conflict in the Middle-East keep pushing the stock lower. Although I believe INMD remains significantly undervalued, the unpredictable situation in Israel as well as a probable FY2024 guidance miss are key risks that warrant caution. I am therefore downgrading INMD to Hold. I remain long for the mid-term upside potential, but I don’t expect upside catalysts before 2025. Read the full article on Seeking Alpha分析記事 • Aug 04
Here's What Analysts Are Forecasting For InMode Ltd. (NASDAQ:INMD) Following Its Earnings Miss
InMode Ltd. ( NASDAQ:INMD ) missed earnings with its latest second-quarter results, disappointing overly-optimistic...Seeking Alpha • Jun 13
InMode: Reversing Previous Shareholder Dilution With Buybacks
Summary Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals, leading to lower revenue growth projections for 2024. The company's new share repurchase program should reverse the dilution shareholders previously experienced. The low expectations embedded into the company's valuation makes it ripe for a revision higher. Read the full article on Seeking Alpha分析記事 • May 29
Lacklustre Performance Is Driving InMode Ltd.'s (NASDAQ:INMD) Low P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 18x, you may...Seeking Alpha • May 08
InMode: Facing A Myraid Of Headwinds
Summary InMode's growth has plummeted due to sales execution issues, manufacturing delays, reduced demand, and high interest rates. INMD's business seems heavily reliant on economic conditions, beyond management's control. Shareholders expressed frustration with management's capital allocation decisions. I rate the company as a hold for now. Read the full article on Seeking AlphaSeeking Alpha • Apr 27
InMode: More Headwinds Than Expected, Wait For A Floor To Materialize (Rating Downgrade)
Summary The market remains pessimistic about INMD's prospects, as observed in the stock's decline by -21.6% over the past three months, well underperforming the wider market at +4.7%. Part of the headwinds are attributed to the management's lowered FY2024 revenue guidance, building upon the FY2023 slowdown, as borrowing costs are still elevated for prospective buyers. Then again, we believe that consumer demand for skin-tightening devices and body contouring products may remain robust, thanks to the popularity of GLP-1 obesity therapies. The same has been observed in INMD's growing consumable sales, with it likely to drive intermediate-term growth as equipment sales temporarily stall. However, with the stock recording elevated short interest and the market experiencing an uncertain pullback, it may be more prudent to wait for a floor to materialize first. Read the full article on Seeking AlphaSeeking Alpha • Apr 03
InMode's Quest For Growth Amidst Aesthetic Adversities
Summary InMode's Q4 revenue dropped YOY; management optimistic about new platforms despite industry challenges. High dependence on U.S. revenue from minimally invasive procedures; facing increasing competition in RF technology. R&D spending at 3% of revenue, below industry norm; sales and marketing costs rising. Investment stance: Hold, pending revenue diversification and increased R&D investment focus. Read the full article on Seeking AlphaSeeking Alpha • Mar 26
InMode Does Not Look Pretty Right Now: Time To Buy
Summary Despite a highly profitable business model and a strong position in the medical aesthetics industry, INMD stock is down -33% over the last 12 months. Macroeconomic pressures, political risks in InMode’s home country Israel, and, to a lesser extent, suboptimal capital allocation have caused the stock to plummet. InMode continues to deliver cutting-edge innovation and expand its commercial capabilities, steadily gaining market share. Even without a share buyback program, INMD is grossly undervalued unless you believe the conflicts in Israel will escalate. With a fair value of $31 (range $25 to $39), it is time to buy INMD while most investors paint an ugly outlook for this aesthetics leader. Read the full article on Seeking AlphaSeeking Alpha • Feb 16
InMode: Q4 Earnings Beat Not Enough - Macro Outlook Key To Buy Signal
Summary InMode beats revenue and EPS estimates in Q4 2023 earnings report. Q4 revenue is down 5% YoY and non-GAAP EPS is down 9% YoY. InMode maintains impressive gross margin of 84% and sees 20% YoY growth in revenue from consumables and services. Despite beating the lowered Q4 2023 expectations, InMode is facing challenging conditions with a weak 2024 outlook. Read the full article on Seeking Alpha決済の安定と成長
配当データの取得
安定した配当: INMDの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: INMDの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| InMode 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (INMD) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Medical Equipment) | 2.2% |
| アナリスト予想 (INMD) (最長3年) | 0% |
注目すべき配当: INMDは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: INMDは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: INMDの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: INMDが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 12:42 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
InMode Ltd. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| null null | Baird |
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |